| TIME |
TOPIC |
SPEAKER |
| 6:15 am | Breakfast | |
| 6:30 am - 9:00 am | Poster & Sponsor Set up | |
|
6:45 am - 7:45 am
|
Satellite 1 | Cytokinetics: Multidisciplinary Insights: Best Practices for Diagnosing and Managing Obstructive Hypertrophic Cardiomyopathy |
Mariko Harper, MD, MS, FACC
Katie Halbmaier, DNP, ARNP, ACGN
Margaret Kurnides, RDCS, ACS, FASE |
| 7:45 am - 8:00 am |
Coffee Break |
|
| 8:00 am |
Opening Remarks |
Milind Desai, Anjali Owens |
|
Session 1: Multimodality Imaging for Diagnosis, Risk Stratification and Management of Hypertrophic Cardiomyopathy |
Moderators: Jeffrey Geske, Martin Maron |
| 8:12 am |
New perspectives on diagnosis and differential diagnosis of HCM: Artificial intelligence to the rescue? |
James Moon |
| 8:24 am |
Unmasking a masquerader: leveraging multimodality imaging to characterize phenocopies |
Ahmad Masri |
| 8:36 am |
Sudden death risk assessment and multimodality imaging: Reconciling recommendations across the pond |
Betty Raman |
| 8:48 am |
The good the bad, and the ugly of imaging a CMI patient |
Milind Desai |
| 9:00 am |
Moderated discussion |
All |
| 9:15 am |
Break |
|
|
Session 2: Impact of Genetics on the Family – from Mendelian to Polygenic |
Moderators: Sharon Cresci, Michele Michels |
| 9:30 am |
How has the bench helped us be better at the bedside? |
Jolanda Van der Velden |
| 9:42 am |
The basics of pediatric HCM: Who, what, when, where, why? |
Joe Rossano |
| 9:54 am |
Emerging concepts in genetic testing: The new ground truth or still works in progress? |
Jodie Ingles |
| 10:06 am |
Leveraging polygenic risk scores in HCM: Is more the merrier? |
James Ware |
| 10:18 am |
Facilitated discussion |
Sharon Cresci, Michele Michels |
| 10:30 am |
The Inaugural Eugene Braunwald Lecture |
Prof. Hugh Watkins |
| 11:00 am - 12:30 am |
Lunch/Posters/Sponsor Visits |
|
| 11:30 am - 12:30 pm |
Satellite 2 | BMS: Real-World Impact of Cardiac Myosin Inhibitors in Adults with Symptomatic NYHA Class II-III Obstructive HCM: A Case-Based Discussion |
Theodore Abraham, MD, FACC, FASE |
| 12:30 pm |
Break |
|
|
Session 3: Approved and Novel Therapies for the Management of Obstructive and Nonobstructive HCM |
Moderators: Sharlene Day, Andrew Wang |
| 12:45 pm |
More (Aerobic) Power to the People |
James MacNamara |
|
12:57 pm
|
CMIs in Obstructive HCM: Exploring Sequoia trees with Valor while enjoying Maple syrup |
Sara Saberi |
| 1:09 pm |
Treatment of nonobstructive HCM: Where are we? And where do we go? |
Anjali Owens |
| 1:21 pm |
Invasive Therapies for Obstructive HCM : A shave, a tuck or a squirt ? |
Nick Smedira |
| 1:33 pm |
Debate: What path for which patient as an initial option |
Moderator: Andrew Wang |
| |
CMI debater (10 minutes) |
Matthew Martinez |
| |
SRT debater (10 minutes) |
Steve Ommen |
| 1:55 pm |
Panel Discussion: HCM is a Team Sport |
Moderators: Jane Linderbaum, Ted Abraham. Panelists: Erin Davidson, PharmD; Alex de Feria; Susan Ospina, NP; Ozlem Bilen |
|
2:25 pm
|
Break |
|
|
Oral Abstracts with moderated discussion |
Moderators: Carolyn Ho, Nosheen Reza |
| 2:40 pm |
Characteristics and Long-Term Outcomes of Asymptomatic Patients with Hypertrophic Cardiomyopathy Undergoing Treadmill Stress Echocardiography |
Sana Sultana |
| 2:50 pm |
Long-term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM |
Shepard Weiner |
| 3:00 pm |
Dual SGLT1 and 2 Inhibition with Sotagliflozin Ameliorates Adverse Cardiac Remodeling and Diastolic Dysfunction in Mice with HCM Due to Tropomyosin E180G Mutation
|
Fuzhong Qin |
| 3:10 pm |
Artificial intelligence versus clinician maximum wall thickness measurement on cardiac MRI for mortality prediction |
George Joy |
| 3:20 pm |
Body Mass Index, Diastolic Blood Pressure, and Hypertrophic Cardiomyopathy Polygenic Background Differentially Modify Hypertrophic Cardiomyopathy Risk |
Sarah Abramowitz |
| 3:30 pm |
Break |
|
|
Session 4: Complications of Hypertrophic Cardiomyopathy: Recognition and Treatment of Arrhythmias and Advanced Heart Failure |
Moderators Mariko Harper, Anna Woo
|
| 3:45 pm |
Rowin' Troubled Rivers: AF in HCM is a bad actor |
Ethan Rowin |
| 3:57 pm |
Afib and VT management in the eyes of EP: Monitor, medicate, anticoagulate, and ablate |
Fatima Ezzeddine |
| 4:09 pm |
Navigating the bridge too far: Advanced heart failure and transplantation |
Jorge Silva Enciso |
| 4:21 pm |
ICD selection: the right wire for the right warrior |
Mark Link |
| 4:33 pm |
Moderated discussion |
All |
|
Session 5: Managing Double Trouble - How the Experts Approach Complex Cases |
Moderators Richard Bach, Melissa Burroughs |
| 4:45 pm |
Severe aortic stenosis and obstructive HCM |
Srihari Naidu |
| 4:52 pm |
Severe oHCM and severe CAD: Navigating complex LGE pattern |
Albree Tower Rader |
| 5:01 pm |
Amyloid and HCM |
Florian Rader |
| 5:08 pm |
Fabry and HCM |
Daniele Massera |
| 5:15 pm |
What makes the Fabry heart tick? |
John L. Jefferies |
|
Late Breaking Oral Abstracts |
Moderators: Michele Michels, Amrut Ambardekar |
| 6:00 pm |
Effect of Mavacamten on Measures of Cardiopulmonary Exercise Testing: An Analysis of the ODYSSEY-HCM Randomized Trial
|
Anjali Owens |
| 6:08 pm |
Polygenic Risk Enhances Penetrance and Prognosis in Hypertrophic Cardiomyopathy: Insights from a US-based Multi-Ancestry Cohort |
Harshvir Bal |
| 6:16 pm |
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy |
Michael Nassif |
| 6:24 pm |
Effect of selected baseline characteristics and exposure on efficacy and safety of mavacamten: A Post-Hoc Analysis from the ODYSSEY trial |
Milind Desai |
| 6:30 pm - 7:30 pm |
Reception and Posters (reception is courtesy of Sanofi) |
|
.jpg)
.jpg)
